Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Marlana Orloff"'
Autor:
Anthony M. Joshua, Jessica C. Hassel, John M. Kirkwood, Sophie Piperno-Neumann, Christopher J. Holland, Richard D. Carvajal, Sebastian Ochsenreither, Alexander N. Shoushtari, Omid Hamid, Max Schlaak, Shaad Essa Abdullah, Jean-François Baurain, Reinhard Dummer, Ryan J. Sullivan, Marcus O. Butler, Howard Goodall, Piotr Rutkowski, Paul C. Nathan, Marlana Orloff, Joseph J. Sacco
Publikováno v:
Journal of Clinical Oncology. 39:9527-9527
9527 Background: Tebe is a bispecific consisting of an affinity-enhanced T cell receptor fused to an anti-CD3 effector that can redirect T cells to target gp100+ cells. In this Phase (Ph) 3, randomized trial of first line (1L) metastatic uveal melano
Autor:
John M. Kirkwood, Ryan J. Sullivan, Jessica C. Hassel, Shaad Essa Abdullah, Piotr Rutkowski, Sophie Piperno-Neumann, Joseph J. Sacco, Max Schlaak, Marcus O. Butler, Josep M. Piulats, Sebastian Ochsenreither, Jean-François Baurain, Anthony M. Joshua, Paul C. Nathan, Reinhard Dummer, Sarah Lockwood, Alexander N. Shoushtari, Marlana Orloff, Mughda Deo
Publikováno v:
Journal of Clinical Oncology. 39:9509-9509
9509 Background: Tebentafusp (tebe) is the first T cell receptor (TCR) therapeutic to demonstrate an overall survival (OS) benefit in a randomized Phase 3 (Ph3) study [ NCT03070392 ]. In Ph2, 42% of pts with best overall response (BOR) of progressive
Autor:
Marcus O. Butler, Marlana Orloff, Claire Watkins, Howard Goodall, Alexander N. Shoushtari, Joseph J. Sacco, Richard D. Carvajal, Max Schlaak, Shaad Essa Abdullah
Publikováno v:
Journal of Clinical Oncology. 39:9526-9526
9526 Background: Tebentafusp (tebe) is a bispecific consisting of an affinity-enhanced T cell receptor fused to an anti-CD3 effector that can redirect T cells to target gp100+ cells. Tebe significantly improved OS compared to investigator’s choice
Autor:
Leonel Hernandez-Aya, Pippa Corrie, M Sznol, Richard D. Carvajal, Namir J. Hassan, Jeff Evans, Middleton, Omid Hamid, C Mulatero, Alexander N. Shoushtari, Cheryl McAlpine, David Krige, Neil Steven, Joseph J. Sacco, N Little, J. R. Infante, Marlana Orloff, CM Coughlin, Takami Sato, Paul Nathan, Sandip Pravin Patel, A-M Hulstine
Publikováno v:
Journal for ImmunoTherapy of Cancer. 5
Autor:
Marlana Orloff, Samuel Pan, Richard D. Carvajal, Jessica Yang, Takami Sato, Paul Nathan, Karla A. Lee, Susana Hernandez, Shahnaz V. Singh-Kandah, Jose Lutzky, Leonel Hernandez-Aya, Sophie Merrick, Alexandra Nesson, Joseph J. Sacco, Mark R. Middleton
Publikováno v:
Journal of Clinical Oncology. 37:9592-9592
9592 Background: ICI responses in UM are rare (~5% with anti-CTLA4/PD1 monotherapy; 10-12% with combination ICI). IMC is a bispecific agent composed of a high affinity T cell receptor targeting the gp100 melanoma antigen fused to an anti-CD3 scFv tha
Autor:
Paul Nathan, Leonel Hernandez-Aya, Marlana Orloff, Nicola Little, Jennifer Visich, Ann-Marie Hulstine, Joseph J. Sacco, Christina M. Coughlin, Takami Sato, Richard D. Carvajal
Publikováno v:
Journal of Clinical Oncology. 36:9521-9521
9521Background: IMCgp100 is a bispecific biologic comprised of a soluble T cell receptor recognizing the gp100 antigen fused to a scFV anti-CD3 and redirects T cell lysis of melanoma cells expressi...